The fact that our studies demonstrate potent inhibition of both primary mammary tumor growth and metastasis, would suggest that Mnk1/2 degraders are more likely to achieve more favorable clinical responses than Mnk1/2 inhibitors in breast cancer patients. This evidence concerns the gene MKNK1 and breast cancer.